文献速递脊柱关节炎

幼年脊柱关节炎疾病复发测量工具的开发与验证

Development and Validation of a Juvenile Spondyloarthritis Disease Flare Measure: Ascertaining Flare in Patients With Inactive Disease.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2022-09-13

本研究回顾性分析接受系统治疗降阶梯的幼年脊柱关节炎患儿资料,开发并验证一个复合疾病复发定义。该定义要求5项核心指标中至少3项出现临床有意义恶化,在开发队列中ROC AUC为0.91,验证队列中为0.85,显示良好的判别效度,可用于识别降阶梯治疗后的疾病复发。

要点

  • 幼年SpA复发定义要求5项核心指标中至少3项临床有意义恶化。
  • 开发队列ROC AUC 0.91,验证队列ROC AUC 0.85,判别效度良好。
  • 该工具可用于临床实践、观察性研究及治疗试验中识别疾病复发。

核心结论

  • 幼年SpA复发测量工具在降阶梯治疗患者中识别疾病复发具有初步效度支持。

研究设计与样本

  • 回顾性图表回顾研究,开发队列来自1个中心,验证队列来自4个中心,均为大型三级医疗系统。

主要发现

  • 开发队列中ROC AUC为0.91,PPV 87.5%,NPV 98.1%,敏感性82.4%,特异性98.7%。
  • 验证队列中ROC AUC为0.85,PPV 92.3%,NPV 96.8%。
  • Cronbach's α为0.81,因子分析显示该结局测量单一构念。
  • 21名儿科风湿病学家调查显示该工具具有表面效度。

关键数值与推荐

  • 复发定义:以下5项核心指标中至少3项出现临床有意义恶化:照护者/患者对健康状况的评估、医生对疾病活动度的评估、照护者/患者对疼痛的评估、躯体功能、活动关节计数。
  • 参考标准:医生评估为活动性疾病并重新开始标准剂量系统治疗。

临床怎么用

  • 该工具可用于幼年SpA患者降阶梯治疗后识别疾病复发,辅助临床决策。
  • 潜在适用于临床实践、观察性研究和治疗试验。

局限性

  • 本研究为回顾性设计,样本来自大型三级医疗系统,外推性需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Our objective was to develop and validate a composite disease flare definition for juvenile spondyloarthritis (SpA) that would closely approximate the clinical decision made to reinitiate or not reinitiate systemic therapy after therapy de-escalation. METHODS: Retrospective chart reviews of children with SpA who underwent systemic therapy de-escalation of biologic or conventional disease-modifying antirheumatic drugs were used to develop and validate the flare outcome. Data on independent cohorts for development (1 center) and validation (4 centers) were collected from large tertiary health care systems. Core measure thresholds and candidate disease flare outcomes were assessed using sensitivity, specificity, positive predictive values (PPVs) and negative predictive values (NPVs), and the receiver operating characteristic (ROC) area under the curve (AUC), with physician assessment of active disease plus re-initiation of standard dose of systemic therapy as the reference standard. RESULTS: Of the candidate definitions, clinically meaningful worsening in ≥3 of the following 5 core measures performed best: caregiver/patient assessment of well-being; physician assessment of disease activity; caregiver/patient assessment of pain, physical function, and active joint count. The ROC AUC was 0.91, PPV 87.5%, NPV 98.1%, sensitivity 82.4%, and specificity 98.7%. Cronbach's α was 0.81, signifying internal consistency, and factor analysis demonstrated that the outcome measured 1 construct. The Juvenile SpA Flare measure had face validity according to 21 surveyed pediatric rheumatologists. Juvenile SpA Flare had an ROC AUC of 0.85, a PPV of 92.3%, and an NPV of 96.8% in the validation cohort. CONCLUSION: There is initial support for the validity of the Juvenile SpA Flare measure as a tool to identify disease flare in juvenile SpA patients de-escalating therapy, and the measure is potentially applicable in clinical practice, observational studies, and therapeutic trials.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Weiss PF, Brandon TG, Ryan ME, et al. Development and Validation of a Juvenile Spondyloarthritis Disease Flare Measure: Ascertaining Flare in Patients With Inactive Disease. Arthritis Care Res (Hoboken). 2022. PMID: 34363343. doi:10.1002/acr.24763

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。